Description
A kit of 10 vials of CJC-1295 with DAC. Each vial contains 5mg of lyophilized CJC-1295 with DAC.
CJC-1295 with DAC is a long-acting analogue of growth hormone-releasing hormone, or GHRH. The "DAC" component, short for Drug Affinity Complex, allows the peptide to bind to albumin in the bloodstream, dramatically extending its half-life compared with short-acting GHRH analogues. This produces a prolonged increase in endogenous growth hormone secretion and downstream IGF-1 levels rather than a brief pulse.
Potential benefits suggested by its mechanism include sustained increases in GH and IGF-1, possible improvements in body composition, fat metabolism, recovery, tissue repair, and sleep-related physiology. CJC-1295 with DAC has published human pharmacology data; early randomized studies in healthy adults showed that a single injection could increase mean plasma GH concentrations for several days and raise IGF-1 for roughly one to two weeks, with repeated dosing producing cumulative effects. The reported effective half-life was on the order of several days, confirming that the DAC modification substantially prolongs activity.
That long duration is also the key biological distinction. Rather than simply amplifying discrete physiological GH pulses, CJC-1295 with DAC raises the overall GH/IGF-1 environment for an extended period.





